# Transcript — Deep research — BRCA1 DNA repair literature survey (English) / 深度研究——BRCA1 DNA 修复文献调研（英文）

- Scenario: `agent-deep-research-en` (kind: agent, lang: en)
- Outcome: **PASS**
- Replay: `node demos/run-demo.mjs --only agent-deep-research-en --publish` (spends LLM tokens; manual-run only)

## Prompt / 提示词

```text
no-interview light-research: Using the bioresearcher-deep-research skill, survey the recent article landscape on BRCA1 DNA repair. Cite sources with PMIDs.
```

## Tool calls (21) / 工具调用

### 1. `skill` — completed

Input:
```json
{"name":"bioresearcher-deep-research"}
```
Output (trimmed):
```text
<skill_content name="bioresearcher-deep-research">
# Skill: bioresearcher-deep-research

# Bioresearcher Deep Research

Reference-based biomedical research: interview the user, split the topic into
research aspects, investigate each aspect with biomcp tools, then synthesize a
succinct, accurately cited report. Harness-agnostic: works with or without a
subagent/Task tool.

## What it does

- Decomposes a biomedical question (disease, drug, gene, variant, trial
  landscape, patent space, dataset) into 2-5 independent research aspects.
- Runs one focused worker per aspect - in parallel via the harness's
… [trimmed 325 more line(s)]
```

### 2. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/worker-protocol.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/worker-protocol.md</path>
<type>file</type>
<content>
1: # Worker Protocol
2: 
3: The canonical contract for per-aspect research workers - both parallel
4: subagents and the sequential fallback in the main conversation.
5: 
6: ## Overview
7: 
8: Each worker owns exactly ONE research aspect of a TOPIC. It queries biomcp
9: tools, collects identifiers, and writes one markdown file under
10: `reports/<TOPIC>/`. Workers never re-delegate, never fabricate, and never fall
11: back to internal knowledge for facts. Workers also never interview the user -
12: clarification is exclusively the orchestrator's Step 1 (SKILL.md).
… [trimmed 101 more line(s)]
```

### 3. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/tool-selection.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/tool-selection.md</path>
<type>file</type>
<content>
1: # Tool Selection
2: 
3: Route a research question to the correct biomcp tool, then shape the call with
4: `sections` / `limit` / pagination so payloads stay small.
5: 
6: ## Overview
7: 
8: biomcp (npm `biomcp`, pinned `biomcp@1.1`) exposes 56 tools: 41 core plus 15
9: environment-gated optional tools (3 database, 4 R analysis, 8 biowasm). This
10: file routes question types to tools; per-domain parameter detail lives in the
11: domain reference files.
12: 
… [trimmed 133 more line(s)]
```

### 4. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/citations.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/citations.md</path>
<type>file</type>
<content>
1: # Citation Formats
2: 
3: Numbered-citation formats per source type, with URL forms.
4: 
5: ## Overview
6: 
7: All findings are cited with numbered in-text markers ([1], [2, 3], [1-5]),
8: numbered by order of appearance, resolved against a bibliography at the end
9: of the document. Each source type has a fixed format so reports stay
10: consistent across workers and aspects.
11: 
12: ## In-text citation forms
… [trimmed 137 more line(s)]
```

### 5. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/report-template.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/report-template.md</path>
<type>file</type>
<content>
1: # Report Template
2: 
3: Mandatory structure for `final_report.md` (and the per-aspect files, in
4: lighter form). Ported from the bioresearcher agent's report standard.
5: 
6: ## Overview
7: 
8: Every report has exactly SIX mandatory sections, in this order. Every claim
9: carries provenance: a citation [N], a documented data source, or a described
10: analysis method.
11: 
12: ## Mandatory sections
… [trimmed 108 more line(s)]
```

### 6. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/article-literature.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/references/article-literature.md</path>
<type>file</type>
<content>
1: # Article & Literature Research
2: 
3: Literature search and retrieval via `article_search` / `article_get`
4: (PubMed, Europe PMC, Semantic Scholar, and more).
5: 
6: ## Overview
7: 
8: `article_search` runs federated search across up to five backends with
9: deduplication; `article_get` retrieves one article by PMID/PMCID/DOI with
10: optional open-access full text, annotations, and citation graphs. Both tools
11: enforce a 30-second execution timeout.
12: 
… [trimmed 80 more line(s)]
```

### 7. `todowrite` — completed

Input:
```json
{"todos":[{"content":"Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server","status":"in_progress","priority":"high"},{"content":"Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)","status":"pending","priority":"high"},{"content":"Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape","status":"pending","priority":"high"},{"content":"Synthesize final_report.md (6 sections, unified bibliography)","status":"pending","priority":"high"},{"content":"Render final_report.html via conversion ladder","status":"pending","priority":"medium"}]}
```
Output (trimmed):
```text
[
  {
    "content": "Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server",
    "status": "in_progress",
    "priority": "high"
  },
  {
    "content": "Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)",
    "status": "pending",
    "priority": "high"
  },
  {
    "content": "Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape",
    "status": "pending",
    "priority": "high"
… [trimmed 12 more line(s)]
```

### 8. `write` — completed

Input:
```json
{"content":"","filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/.gitkeep"}
```
Output (trimmed):
```text
Wrote file successfully.
```

### 9. `biomcp_gene_search` — completed

Input:
```json
{"limit":1,"query":"BRCA1"}
```
Output (trimmed):
```text
[{"symbol":"BRCA1","name":"BRCA1 DNA repair associated","entrez_id":"672"}]
```

### 10. `task` — completed

Input:
```json
{"description":"Aspect 2: BRCA1 therapy landscape","prompt":"You are a per-aspect research worker for a biomedical deep-research pipeline. Do research ONLY (biomcp tool calls + file writes); do not write code.\n\nTOPIC: brca1_dna_repair\nYOUR RESEARCH FOCUS: brca1_therapy_resistance\nDESCRIPTION: Survey the RECENT (2023-01-01 to today, 2026-09-06) journal-article landscape on TRANSLATIONAL/Clinical dimensions of BRCA1-mediated DNA repair: (a) BRCA1-mutant / homologous-recombination-deficient (HRD) cancers and PARP inhibitor (olaparib, talazoparib, niraparib, rucaparib) efficacy; (b) mechanisms and reversal of PARP inhibitor resistance in BRCA1-deficient tumors (restoration mutations incl. BRCA1 reversion, replication fork protection rewiring, loss of 53BP1/Shieldin, drug tolerance); (c) combination strategies overcoming resistance (ATR/WEE1/CHK1 inhibitors, immunotherapy, platinum re-challenge); (d) functional assays and biomarkers for BRCA1/HRD (HRD assays, RAD51 foci, ctDNA); (e) recent phase 2/3 trial reports involving BRCA1-deficient populations. Emphasize 2023-2026 primary papers and authoritative reviews.\n\nWORKER RULES (binding):\n1. Stay focused on this aspect only. Never delegate to other subagents. Do not expand scope.\n2. Query biomcp tools per the cheatsheet below; filter at the source (specific terms, limit, dateRange) - never retrieve broadly and filter locally.\n3. Sequential MCP calls only - never issue concurrent biomcp calls. No manual sleep timers between calls (server-side limiters pace each source).\n4. NO internal knowledge for facts: use only biomcp tool results or official sources. If evidence is missing after retries, say so explicitly in the report. Do NOT fabricate PMIDs, DOIs, or findings - every identifier must come from tool output.\n5. Every claim gets a numbered in-text citation [N] and a bibliography entry. Capture PMIDs/DOIs/NCT IDs as you go.\n6. Retry ladder per query: attempt 1 original; on fail wait a few seconds, attempt 2 sim… [trimmed 2791 more char(s)]
```
Output (trimmed):
```text
<task id="ses_f8abe5e6affeGMpreCotl1y2JK" state="completed">
<task_result>
Report complete.

**Key findings digest:**
- **Reversions dominate acquired resistance:** BRCA1/2 reversion mutations found in 60% of HRD-targeted-therapy-resistant metastatic breast cancer via longitudinal ctDNA, co-occurring with TP53BP1/RIF1/PAXIP1 loss (PMID 38244928); TOPARP-B prostate cancer showed 79% reversion frequency, with POLQ-mediated microhomology signatures (PMID 39577422).
- **Novel BRCA1-specific resistance route:** secondary BRCA1 splice-site mutations drive exon-11 skipping/hypomorph expression, enriched in post-PARPi ARIEL2/ARIEL4 cohorts (PMID 39103848); reversion-independent resistance via DNA pre-replication complex loss is reversible with CDT1/geminin targeting (PMID 40460119).
- **Efficacy gradients within BRCA1:** ovarian cancer BRCA1 RING/BRCT-domain and missense mutations derive the greatest olaparib benefit (PMID 40174507); BRCA1-mutant mCRPC shows shorter olaparib time-on-treatment than BRCA2 (PMID 42609124).
- **Negative phase 2 signal:** neoadjuvant niraparib in HRd ovarian cancer (OPAL cohort C) closed early for futility — ORR 31.6% vs 70.6% for platinum-taxane (PMID 42623963); PRIMA final PROs confirmed preserved QoL on niraparib maintenance (PMID 42385609).
- **Resistance-overcoming combinations:** PARPi+ICI meta-analysis (22 trials) shows BRCA-mutant tumors respond regardless of PD-L1 status (PMID 42639974); ATR+PARPi trials CAPRI (NCT03462342, completed) and TRAP (NCT03787680) target PARPi-resistant disease; CHK1+olaparib synergy in pancreatic models (PMID 42446852).
- **Biomarkers:** functional RAD51 assay predicted pCR in GeparOLA (OR 12.03; PMID 39786436); seven-platform HRD classifier comparison in TNBC reveals method-specific discordance (PMID 42351273); HRD testing is more informative before neoadjuvant chemotherapy (PMID 42418892); scar assays can misclassify (BRCA1-mutant, HRDetect 0.96, yet niraparib-resistant; PMID 42598072).
- **Platinum re-chal… [trimmed 465 more char(s)]
```

### 11. `task` — completed

Input:
```json
{"description":"Aspect 1: BRCA1 HR mechanisms","prompt":"You are a per-aspect research worker for a biomedical deep-research pipeline. Do research ONLY (biomcp tool calls + file writes); do not write code.\n\nTOPIC: brca1_dna_repair\nYOUR RESEARCH FOCUS: brca1_hr_mechanism\nDESCRIPTION: Survey the RECENT (2023-01-01 to today, 2026-09-06) journal-article landscape on the MOLECULAR MECHANISMS of BRCA1 in DNA double-strand break repair / homologous recombination (HR). Research items: (a) BRCA1-BARD1 heterodimer structure/function, ubiquitin signaling, and recruitment to DNA breaks; (b) BRCA1-PALB2-BRCA2-RAD51 axis and HR repair pathway choice vs NHEJ; (c) replication fork protection and fork restart; (d) BRCA1 roles in R-loop resolution and transcription-replication conflicts; (e) liquid-liquid phase separation / condensates at damage sites; (f) notable recent cryo-EM/structural advances. Emphasize high-impact primary papers and authoritative reviews from the last ~3 years.\n\nWORKER RULES (binding):\n1. Stay focused on this aspect only. Never delegate to other subagents. Do not expand scope.\n2. Query biomcp tools per the cheatsheet below; filter at the source (specific terms, limit, dateRange) - never retrieve broadly and filter locally.\n3. Sequential MCP calls only - never issue concurrent biomcp calls. No manual sleep timers between calls (server-side limiters pace each source).\n4. NO internal knowledge for facts: use only biomcp tool results or official sources. If evidence is missing after retries, say so explicitly in the report. Do NOT fabricate PMIDs, DOIs, or findings - every identifier must come from tool output.\n5. Every claim gets a numbered in-text citation [N] and a bibliography entry. Capture PMIDs/DOIs as you go.\n6. Retry ladder per query: attempt 1 original; on fail wait a few seconds, attempt 2 simpler query; attempt 3 alternate source; then record an \"evidence gap\" and continue. Max 3 attempts.\n7. Writing: succinct, accurate, professional aca… [trimmed 2402 more char(s)]
```
Output (trimmed):
```text
<task id="ses_f8abe88ecffehP2C2ZGf58U7El" state="completed">
<task_result>
Report complete — 19 sources, all verified from biomcp tool output.

**Key findings digest:**
- **BRCA1-BARD1 E3 ligase is essential for HDR**: full-length-complex separation-of-function alleles (truly ligase-null vs histone-targeting-impaired) proved the ligase drives end resection AND late HDR stages — Mol Cell 2023, PMID 37797621.
- **Multivalent chromatin recognition**: BARD1 IDR DNA-binding + H2AK15ub/H4K20me0 reading mediates recruitment/ubiquitylation (EMBO J 2023, PMID 37305927); HS-AFM showed BRCA1-BARD1 physically bridges di-nucleosomes to boost E3 activity (NAR 2023, PMID 37823591); CTCF-repressive chromatin cascade licenses rapid BRCA1/BARD1 loading (NAR 2026, PMID 42475683).
- **Pathway choice defined at resection level**: CST complex blocks EXO1 and BLM-DNA2 differentially; BRCA1-BARD1 selectively relieves the EXO1 blockade (Science 2025, PMID 40403056); 53BP1-independent Shieldin-BRCA1 antagonism acts at replication-coupled DSBs (Nat Commun 2026, PMID 42374033).
- **PALB2 IDR is a disordered recombinase**: oligomerization-dependent ssDNA compaction with LLPS potential links BRCA1-axis scaffolding to strand exchange (iScience 2024, PMID 39584160).
- **Fork protection is dynamic**: RNAPII-formed RNA-DNA hybrids shield stalled forks from DNA2 until DDX39A resolves them; DDX39A loss confers chemoresistance in BRCA1/2-deficient cells (Mol Cell 2025, PMID 39706186); RPA exhaustion selectively kills BRCA1-deficient tumors with PARPi (NAR 2026, PMID 42049240).
- **R-loop axis solved structurally**: SETX-BRCA1-BARD1 complex binds and unwinds R-loops (Ser642–BRCT interaction), preventing transcription-replication conflicts (NSMB 2026, PMID 41917467); TRCs are a BRCA1-mutant synthetic-lethal vulnerability via MEPCE/PAF1 (NAR 2023, PMID 36928661).
- **LLPS organizes BRCA1 recruitment**: K63-polyubiquitin-driven RAP80 condensation recruits BRCA1 (NAR 2023, PMID 37638744); RNF168 condensate … [trimmed 532 more char(s)]
```

### 12. `todowrite` — completed

Input:
```json
{"todos":[{"content":"Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server","priority":"high","status":"completed"},{"content":"Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)","priority":"high","status":"completed"},{"content":"Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape","priority":"high","status":"completed"},{"content":"Synthesize final_report.md (6 sections, unified bibliography)","priority":"high","status":"in_progress"},{"content":"Render final_report.html via conversion ladder","priority":"medium","status":"pending"}]}
```
Output (trimmed):
```text
[
  {
    "content": "Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server",
    "status": "completed",
    "priority": "high"
  },
  {
    "content": "Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)",
    "status": "completed",
    "priority": "high"
  },
  {
    "content": "Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape",
    "status": "completed",
    "priority": "high"
… [trimmed 12 more line(s)]
```

### 13. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/brca1_hr_mechanism.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/brca1_hr_mechanism.md</path>
<type>file</type>
<content>
1: # BRCA1 mechanism in homologous recombination (TOPIC: brca1_dna_repair)
2: 
3: ## Scope
4: 
5: This report surveys the journal-article landscape from 2023-01-01 to 2026-09-06 on the molecular mechanisms of BRCA1 in DNA double-strand break (DSB) repair and homologous recombination (HR). Six thematic areas were researched via biomcp literature searches restricted to the date window: (a) BRCA1-BARD1 heterodimer structure/function, ubiquitin signaling, and recruitment to DNA breaks; (b) the BRCA1-PALB2-BRCA2-RAD51 axis and HR pathway choice versus NHEJ; (c) replication fork protection and restart; (d) BRCA1 roles in R-loop resolution and transcription-replication conflicts; (e) liquid-liquid phase separation (LLPS)/condensates at damage sites; and (f) notable recent structural advances. Primary research articles in high-impact journals are emphasized, supplemented by authoritative reviews. All claims below are drawn from biomcp tool output; every identifier was copied directly from search results.
6: 
7: ## Findings
8: 
9: ### (a) BRCA1-BARD1 heterodimer: E3 ligase activity, chromatin recognition, and recruitment to breaks
10: 
11: A landmark study using full-length BRCA1-BARD1 settled the long-standing controversy over the importance of the complex's RING-type E3 ubiquitin ligase activity. Wang et al. showed that previously studied ligase-deficient mutants retain residual activity, and that newly constructed separation-of-function alleles — a truly ligase-null variant and a variant specifically impaired in nucleosomal histone targeting — render cells hypersensitive to DNA-damaging agents; the ligase activity is required not only for DNA end resection during homology-directed repair (HDR) but also for later stages of HDR completion [1]. Mechanistically, multivalen… [trimmed 761 more char(s)]
```

### 14. `read` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/brca1_therapy_resistance.md"}
```
Output (trimmed):
```text
<path>/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/brca1_therapy_resistance.md</path>
<type>file</type>
<content>
1: # BRCA1 deficiency in therapy and resistance (TOPIC: brca1_dna_repair)
2: 
3: ## Scope
4: 
5: This report surveys the translational and clinical literature (journal articles, 2023-01-01 to 2026-09-06) on BRCA1-mediated DNA repair as a therapeutic axis: (a) efficacy of PARP inhibitors (olaparib, talazoparib, niraparib, rucaparib) in BRCA1-mutant / homologous-recombination-deficient (HRD) cancers; (b) mechanisms and reversal of PARP inhibitor (PARPi) resistance, including BRCA1 reversion mutations, replication fork protection rewiring, loss of 53BP1/Shieldin, and drug tolerance; (c) combination strategies to overcome resistance (ATR/WEE1/CHK1 inhibitors, immunotherapy, platinum re-challenge); (d) functional assays and biomarkers of BRCA1/HRD (genomic HRD assays, RAD51 foci, ctDNA); and (e) recent phase 2/3 trial reports in BRCA1/HRD-deficient populations. All searches were executed via the biomcp literature and trial tools; every identifier below is copied from tool output.
6: 
7: ## Findings
8: 
9: ### PARP inhibitor efficacy in BRCA1-mutant/HRD cancers
10: 
11: The magnitude of PARPi benefit in BRCA1/2-mutant ovarian cancer depends on mutation type and functional domain. In a multicenter real-world study of 268 BRCA1/2-mutated ovarian cancer patients (140 olaparib maintenance vs 128 historical controls), BRCA1 mutations in the RING (HR 0.08, 95% CI 0.01-0.75) and BRCT (HR 0.10, 95% CI 0.02-0.38) domains conferred the greatest olaparib benefit, and missense variants (HR 0.04, 95% CI 0.01-0.31) outperformed frameshift/nonsense variants, with no recurrences among p.(Ala1708Glu) BRCT carriers during the study period [1]. Beyond ovarian cancer, a phase II trial of niraparib in advanced pancreatic cancer harboring pathogenic variants in ATM, BRCA1, BRCA2, PALB… [trimmed 1165 more char(s)]
```

### 15. `write` — completed

Input:
```json
{"content":"# Recent article landscape on BRCA1 DNA repair (2023-2026)\n\nGenerated: 2026-09-06 | TOPIC: brca1_dna_repair | Scope: survey of recent (2023-01-01 to 2026-09-06) journal literature on BRCA1 in DNA double-strand break repair / homologous recombination (HR), spanning molecular mechanism and translational/therapeutic landscape.\n\n## Executive Summary\n\nThe 2023-2026 literature redefined BRCA1 DNA repair biology on two fronts. Mechanistically, separation-of-function alleles finally proved the BRCA1-BARD1 E3 ubiquitin ligase is essential for end resection and completion of homology-directed repair [1], and the CST complex was shown to be the critical resection blockade that BRCA1-BARD1 selectively relieves, directly wiring pathway choice to PARP inhibitor response [2]. Translationally, acquired PARP inhibitor resistance in BRCA1-deficient cancers is dominated by genetic restoration of HR — BRCA1/2 reversion mutations in 60% of resistant metastatic breast cancers [3] and 79% of TOPARP-B prostate cancers [4] — reframing resistance monitoring around longitudinal ctDNA.\n\nKey findings:\n- BRCA1-BARD1 ligase activity, multivalent nucleosome bridging, and CTCF-primed chromatin recruitment are now established as coupled, drug-relevant steps of HR [1, 5-7].\n- Fork protection is dynamically regulated (RNA-DNA hybrid shielding resolved by DDX39A) and separable from HR strand exchange [8-10].\n- BRCA1-dependent R-loop resolution (SETX-BRCA1-BARD1 complex) and transcription-replication conflicts have emerged as structural and synthetic-lethal frontiers [11, 12].\n- Phase separation/condensates organize BRCA1-complex recruitment at damage sites [13-15].\n- Clinically, PARPi benefit varies by BRCA1 mutation domain [16], resistance accrues via reversions plus splice-site hijacking and reversion-independent routes [3, 4, 17, 18], and combination (ATR/CHK1 + PARPi, PARPi + immunotherapy) and biomarker (functional RAD51 vs scar assays) strategies are maturing [19, 20].\n\… [trimmed 21720 more char(s)]
```
Output (trimmed):
```text
Wrote file successfully.
```

### 16. `edit` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/final_report.md","newString":"- Fork protection is dynamically regulated (RNA-DNA hybrid shielding resolved by DDX39A) and mechanistically separable from HR strand exchange [13-15].\n- BRCA1-dependent R-loop resolution (SETX-BRCA1-BARD1 complex) and transcription-replication conflicts have emerged as structural and synthetic-lethal frontiers [16, 17].\n- Phase separation/condensates organize BRCA1-complex recruitment at damage sites [18-20].\n- Clinically, PARPi benefit varies by BRCA1 mutation domain [22], resistance accrues via reversions plus splice-site hijacking and reversion-independent routes [3, 4, 27, 28], and combination (ATR/CHK1 + PARPi, PARPi + immunotherapy) and biomarker (functional RAD51 vs scar assays) strategies are maturing [32, 33, 39, 40].","oldString":"- Fork protection is dynamically regulated (RNA-DNA hybrid shielding resolved by DDX39A) and separable from HR strand exchange [8-10].\n- BRCA1-dependent R-loop resolution (SETX-BRCA1-BARD1 complex) and transcription-replication conflicts have emerged as structural and synthetic-lethal frontiers [11, 12].\n- Phase separation/condensates organize BRCA1-complex recruitment at damage sites [13-15].\n- Clinically, PARPi benefit varies by BRCA1 mutation domain [16], resistance accrues via reversions plus splice-site hijacking and reversion-independent routes [3, 4, 17, 18], and combination (ATR/CHK1 + PARPi, PARPi + immunotherapy) and biomarker (functional RAD51 vs scar assays) strategies are maturing [19, 20]."}
```
Output (trimmed):
```text
Edit applied successfully.
```

### 17. `edit` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/final_report.md","newString":"DDX39A loss enhances fork protection and chemoresistance in BRCA1/2-deficient cells [13].","oldString":"DDX39A loss enhances fork protection and chemoresistance in BRCA1/2-deficient cells [8→13]*."}
```
Output (trimmed):
```text
Edit applied successfully.
```

### 18. `edit` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/final_report.md","newString":"derived the greatest olaparib maintenance benefit [22].","oldString":"derived the greatest olaparib maintenance benefit [16→22]*."}
```
Output (trimmed):
```text
Edit applied successfully.
```

### 19. `edit` — completed

Input:
```json
{"filePath":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/reports/brca1_dna_repair/final_report.md","newString":"and CCDC6 immunostaining plus RAD51 testing may widen PARPi eligibility to BRCA1/2-wild-type HGSOC [43].\n\n## Limitations","oldString":"and CCDC6 immunostaining plus RAD51 testing may widen PARPi eligibility to BRCA1/2-wild-type HGSOC [43].\n\n\\* Section-local renumbering note: bracketed numbers refer to the unified References list below.\n\n## Limitations"}
```
Output (trimmed):
```text
Edit applied successfully.
```

### 20. `bash` — completed

Input:
```json
{"command":"command -v uv && uv run --with markdown python \"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1/.opencode/skills/bioresearcher-deep-research/scripts/markdown-to-html.py\" reports/brca1_dna_repair/final_report.md -o reports/brca1_dna_repair/final_report.html && ls -la reports/brca1_dna_repair/","workdir":"/home/administrator/git/bioresearcher-agent/bioresearcher-skills/demos/.runs/agent-deep-research-en/20260906-134601-r1"}
```
Output (trimmed):
```text
/home/administrator/.local/bin/uv
Installed 1 package in 4ms
wrote reports/brca1_dna_repair/final_report.html
total 100
drwxrwxr-x 2 administrator administrator  4096 Sep  6 13:54 .
drwxrwxr-x 3 administrator administrator  4096 Sep  6 13:46 ..
-rw-rw-r-- 1 administrator administrator     0 Sep  6 13:46 .gitkeep
-rw-rw-r-- 1 administrator administrator 17361 Sep  6 13:51 brca1_hr_mechanism.md
-rw-rw-r-- 1 administrator administrator 19948 Sep  6 13:51 brca1_therapy_resistance.md
-rw-rw-r-- 1 administrator administrator 25573 Sep  6 13:54 final_report.html
-rw-rw-r-- 1 administrator administrator 23358 Sep  6 13:54 final_report.md

```

### 21. `todowrite` — completed

Input:
```json
{"todos":[{"content":"Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server","priority":"high","status":"completed"},{"content":"Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)","priority":"high","status":"completed"},{"content":"Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape","priority":"high","status":"completed"},{"content":"Synthesize final_report.md (6 sections, unified bibliography)","priority":"high","status":"completed"},{"content":"Render final_report.html via conversion ladder","priority":"medium","status":"completed"}]}
```
Output (trimmed):
```text
[
  {
    "content": "Create reports/brca1_dna_repair/.gitkeep + smoke-test biomcp server",
    "status": "completed",
    "priority": "high"
  },
  {
    "content": "Aspect 1 worker: BRCA1 mechanism/structure in HR (recent literature)",
    "status": "completed",
    "priority": "high"
  },
  {
    "content": "Aspect 2 worker: BRCA1 deficiency therapy/resistance landscape",
    "status": "completed",
    "priority": "high"
… [trimmed 12 more line(s)]
```

## Final answer (verbatim) / 最终回答（原文）

Done — light-research run complete (interview skipped per prefix, top-2 aspects only).

**Artifacts** (all under `reports/brca1_dna_repair/`):
- `final_report.md` + `final_report.html` (rendered via uv, 25 KB) — 6-section synthesis, 43 sources (40 articles with PMIDs/DOIs + 3 NCT records)
- `brca1_hr_mechanism.md` — mechanism worker (19 sources)
- `brca1_therapy_resistance.md` — therapy/resistance worker (24 sources)

**Headline findings (2023–2026):**
- **Mechanism:** BRCA1-BARD1 E3 ligase proven essential for HDR via separation-of-function alleles (PMID 37797621); CST blockade relieved by BRCA1-BARD1 defines pathway choice (Science, PMID 40403056); SETX-BRCA1-BARD1 R-loop resolution (PMID 41917467); LLPS organizes recruitment (PMIDs 37638744, 38968116)
- **Clinical:** BRCA1/2 reversions in 60% of resistant metastatic breast cancer (PMID 38244928) and 79% in TOPARP-B prostate (PMID 39577422); BRCA1 splice-site hijacking (PMID 39103848); functional RAD51 assay predicts pCR (PMID 39786436); PARPi+ICI works in BRCA-mutant tumors regardless of PD-L1 (PMID 42639974)

**Documented gaps:** no BRCA1-specific cryo-EM paper in-window; Semantic Scholar rate-limited (PubMed/Europe PMC used); only 2 aspects per `light-research`.
